Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 7/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23701236 | 0.92 | HRH3 (0.45) | HRH3CYP4F2CYP4A11FFAR4F10 | |
| SCHEMBL23537968 | 0.88 | ESR1 (0.46) | HRH3CYP4F2CYP4A11F10PLG | |
| SCHEMBL23701302 | 0.87 | ADRA2A (0.42) | HRH3CYP4F2CYP4A11FFAR4F10 | |
| SCHEMBL30951856 | 0.86 | NR1H2 (0.53) | HRH3CYP4F2CYP4A11PORCNESR2 | |
| SCHEMBL23561871 | 0.86 | NR1H2 (0.53) | HRH3CYP4F2CYP4A11PORCNESR2 | |
| SCHEMBL29097949 | 0.86 | HRH3 (0.43) | HRH3CYP4F2CYP4A11F10PLG | |
| SCHEMBL23561872 | 0.82 | STS (0.42) | HRH3ESR1MEN1MAPTKMT2A | |
| SCHEMBL29098045 | 0.81 | F10 (0.52) | HRH3F10PLGESR1 | |
| SCHEMBL23561725 | 0.80 | HRH3 (0.55) | HRH3F10PORCNESR1ESR2 | |
| SCHEMBL23561999 | 0.79 | ESR2 (0.45) | HRH3F10ESR1ESR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992535-B2 | Compounds and probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210236663-A1 | COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236663-A1 | COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | HRH3 3299/4885CYP4F2 4719/4885CYP4A11 4880/4885 |
| US-11992535-B2 | Compounds and probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | HRH3 3299/4885CYP4F2 4719/4885CYP4A11 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.